(0.24%) 5 143.75 points
(0.15%) 38 500 points
(0.35%) 17 908 points
(0.05%) $83.89
(0.57%) $1.934
(0.26%) $2 353.40
(0.39%) $27.64
(2.04%) $940.95
(-0.13%) $0.933
(-0.32%) $10.99
(-0.31%) $0.798
(1.26%) $93.03
-0.19% $ 42.40
Live Chart Being Loaded With Signals
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally...
Stats | |
---|---|
Объем за сегодня | 26 688.00 |
Средний объем | 43 979.00 |
Рыночная капитализация | 1.59B |
EPS | $0 ( 2024-01-25 ) |
Дата следующего отчета о доходах | ( $0.310 ) 2024-05-28 |
Last Dividend | $12.81 ( 2018-12-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | 34.75 |
ATR14 | $0.0200 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Sell | 712 500 | Warrant (right to buy) |
2010-11-04 | Sun Pharmaceutical Industries Ltd | Buy | 5 159 765 | Ordinary Shares |
2010-11-01 | Franklin Resources Inc | Sell | 5 159 765 | Ordinary Shares |
INSIDER POWER |
---|
0.00 |
Last 84 transactions |
Buy: 16 575 249 | Sell: 25 681 902 |
Объем Корреляция
Taro Pharmaceutical Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Taro Pharmaceutical Корреляция - Валюта/Сырье
Taro Pharmaceutical Финансовые показатели
Annual | 2023 |
Выручка: | $572.95M |
Валовая прибыль: | $268.32M (46.83 %) |
EPS: | $0.680 |
FY | 2023 |
Выручка: | $572.95M |
Валовая прибыль: | $268.32M (46.83 %) |
EPS: | $0.680 |
FY | 2022 |
Выручка: | $561.35M |
Валовая прибыль: | $293.12M (52.22 %) |
EPS: | $1.550 |
FY | 2021 |
Выручка: | $548.97M |
Валовая прибыль: | $296.66M (54.04 %) |
EPS: | $-10.12 |
Financial Reports:
No articles found.
Taro Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $12.81 | 2018-12-10 |
Last Dividend | $12.81 | 2018-12-10 |
Next Dividend | $0 | N/A |
Payout Date | 2018-12-28 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $12.81 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.22 | -- |
Div. Sustainability Score | 5.86 | |
Div.Growth Potential Score | 2.19 | |
Div. Directional Score | 4.03 | -- |
Year | Amount | Yield |
---|---|---|
2018 | $12.81 | 12.40% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0748 | 1.500 | 8.50 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0211 | 1.200 | 9.30 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0261 | 1.500 | -0.821 | -1.231 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.03 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.022 | 1.500 | 5.43 | 8.15 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -2.55 | 1.000 | -2.05 | -2.05 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.80 | 2.00 | 8.73 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.29 | 2.00 | 8.86 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.480 | 1.000 | 5.33 | 5.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0360 | 1.000 | -1.280 | -1.280 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.282 | 0.800 | -1.451 | -1.161 | [0.5 - 2] |
Total Score | 5.86 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.87 | 1.000 | 6.58 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0261 | 2.50 | -0.528 | -1.231 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.29 | 2.00 | 9.24 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.80 | 2.00 | 8.73 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.769 | 1.500 | -8.46 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.234 | 1.000 | 6.65 | 0 | [0.1 - 0.5] |
Total Score | 2.19 |
Taro Pharmaceutical
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа